| Drug-perturbation-based stratification of blood cancer S Dietrich, M Oleś, J Lu, L Sellner, S Anders, B Velten, B Wu, J Huellein, ... The Journal of clinical investigation 128 (1), 427-445, 2018 | 151 | 2018 |
| Recurrent CDKN1B (p27) mutations in hairy cell leukemia S Dietrich, J Hüllein, SCW Lee, B Hutter, D Gonzalez, S Jayne, MJS Dyer, ... Blood 126 (8), 1005-1008, 2015 | 96 | 2015 |
| Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ... Leukemia, 2017 | 86 | 2017 |
| Gain of CTCF-Anchored Chromatin Loops Marks the Exit from Naive Pluripotency A Pękowska, B Klaus, W Xiang, J Severino, N Daigle, FA Klein, M Oleś, ... Cell Systems 7 (5), 482-495, 2018 | 70 | 2018 |
| Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity L Möhrmann, M Werner, M Oleś, A Mock, S Uhrig, A Jahn, S Kreutzfeldt, ... Nature Communications 13 (1), 1-15, 2022 | 28 | 2022 |
| Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma K Tomska, R Kurilov, KS Lee, J Hüllein, M Lukas, L Sellner, T Walther, ... Scientific reports 8 (1), 1-12, 2018 | 28 | 2018 |
| Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers A Jahn, A Rump, TJ Widmann, C Heining, P Horak, B Hutter, ... Annals of Oncology, 2022 | 27 | 2022 |
| Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies M Lukas, B Velten, L Sellner, K Tomska, J Hüellein, T Walther, L Wagner, ... Leukemia 34 (11), 2934-2950, 2020 | 20 | 2020 |
| Dissection of CD20 regulation in lymphoma using RNAi M Słabicki, KS Lee, A Jethwa, L Sellner, F Sacco, T Walther, J Hüllein, ... Leukemia 30 (12), 2409, 2016 | 18 | 2016 |
| Neural lineage induction reveals multi-scale dynamics of 3D chromatin organization A Pękowska, B Klaus, FA Klein, S Anders, M Oleś, LM Steinmetz, ... bioRxiv, 004168, 2014 | 3 | 2014 |
| DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS S Dietrich, M Oleś, L Sellner, S Anders, J Lu, B Velten, A Mock, C Oakes, ... Hematological Oncology 35, 56-56, 2017 | 1 | 2017 |
| 1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials RF Schlenk, M Oleś, S Bauer, T Kindler, F Klauschen, CH Brandts, ... Annals of Oncology 34, S1042, 2023 | | 2023 |
| 131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort M Rübsam, M Rheinnecker, B Hutter, M Fröhlich, CE Heilig, ... Annals of Oncology 34, S233, 2023 | | 2023 |
| 1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling M Renner, M Oleś, N Paramasivam, A Schneider, CE Heilig, C Modugno, ... Annals of Oncology 34, S1040, 2023 | | 2023 |
| Genomics-based personalized oncology of advanced thymic epithelial tumors L Möhrmann, L Rostock, M Oleś, A Jahn, M Arlt, N Paramasivam, ... Cancer Research 83 (7_Supplement), 926-926, 2023 | | 2023 |
| Genomics based personalized oncology of cancer of unknown primary M Werner, L Möhrmann, M Oleś, A Mock, A Jahn, S Kreutzfeldt, S Uhrig, ... Cancer Research 80 (16), 2020 | | 2020 |
